Document is current

Any future updates will be listed below

Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study

Crossref DOI link: https://doi.org/10.1007/s10549-025-07628-3

Published Online: 2025-02-03

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark